Choline Cognitive Performance Randomized Trial: What the Evidence Says

Quick Answer

Choline Cognitive Performance Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• It is commonly defined as the presence of clinically relevant depressive symptoms that do not meet the full diagnostic criteria for major depressive disorder (MDD) yet are associated with measurable distress and functional impairment. [Fleishhacker Filippo (2026); evidence level 4]
• Recent meta-analytic evidence indicates that subthreshold depressive symptoms affect nearly 15-20% of older individuals, with higher prevalence rates observed in primary care and institutional settings. [Fleishhacker Filippo (2026); evidence level 4]
• Although L-α-GPC has been discussed in both neurodegenerative and vascular-related cognitive disorders, the available evidence remains heterogeneous. [Putri Vannisa Artasya (2026); evidence level 4]
• Therefore, a careful and contextualized interpretation of the literature is necessary, particularly when comparing evidence across Alzheimer's disease, Parkinson's disease-related cognitive decline, and cognitive impairment associated with cerebrovascular conditions. [Putri Vannisa Artasya (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For choline cognitive performance randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Fleishhacker Filippo (2026). Choline Alfoscerate in the Treatment of Subthreshold Depression in the Elderly: A Pilot Study (CARTESIO). DOI: 10.3390/jcm15114037. PMCID: PMC13258180. PMID: 42278899. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13258180/
• Putri Vannisa Artasya (2026). L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. DOI: 10.2147/NDT.S579603. PMCID: PMC13200208. PMID: 42199923. License: https://creativecommons.org/licenses/by-nc/4.0/ https://www.dovepress.com/terms.php http://creativecommons.org/licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13200208/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.